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Background: Many studies have shown that clinical characteristics and outcomes differ depending on pathologic
variants of focal segmental glomerulosclerosis (FSGS). However, these are not well defined in Asian populations.
Methods: This retrospective study evaluated clinical features and outcomes of pathologic FSGS variants in 111
adult patients between January 2004 and December 2012. Primary outcome was the composite of doubling of
baseline serum creatinine concentrations (D-SCr) or onset of end-stage renal disease (ESRD). Secondary outcome
included complete (CR) or partial remission (PR).
Results: There were 70 (63.1%), 20 (18.0%), 17 (15.3%), 3 (2.7%), and 1 (0.9%) patients with not-otherwise specified
(NOS), tip, perihilar, cellular, and collapsing variants, respectively. At presentation, nephrotic-range proteinuria
occurred more commonly in tip lesion than in other variants. The overall 5-year renal survival rate was 76.8%.
During a median follow-up of 34.5 months, only 1 (5.0%) patient with a tip lesion reached the composite end point
compared to 2 (11.8%) and 12 (17.1%) patients in perihilar and NOS variants, but this difference was not statistically
significant in an adjusted Cox model. However, tip lesion was associated with a significantly increased probability of
achieving CR (P = 0.044).
Conclusion: Similar to other populations, Korean adult patients with FSGS have distinct clinical features with the
exception of a rare frequency of cellular and collapsing variants. Although pathologic variants were not associated
with overall outcome, the tip variant exhibited favorable outcome in terms of achieving remission. Further studies
are required to delineate long-term outcome and response to treatment of the pathologic variants.
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Focal segmental glomerulosclerosis (FSGS) is one of the
most common glomerular diseases leading to end-stage
renal disease (ESRD); accounting for 20 to 25% of adult
patients undergoing kidney biopsy for evaluation of idio-
pathic glomerulonephritis (GN) [1]. The estimated inci-
dence of FSGS is 7 per 1 million in the United States [2]* Correspondence: yoosy0316@yuhs.ac
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unless otherwise stated.and 5.6% of primary glomerular diseases in Korea [3]. A
key pathological finding of FSGS on light microscopy is
a segmental obliteration involving some portion of glom-
erular capillaries by the extracellular matrix, but not all
glomeruli [4,5]. On electron microscopy, diffuse efface-
ment of foot-process without other abnormalities in the
glomerular basement membrane is a prominent finding [5].
It is essentially considered a ‘podocytopathy’, which is asso-
ciated with various insults directed to podocytes [6]; how-
ever, the idiopathic form is most common. The underlying
cause of FSGS is uncertain although circulating permeabil-
ity factors may play a major role in its pathogenesis [7].
The clinical manifestation of FSGS is quite heterogeneous,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and/or microscopic hematuria to heavy proteinuria ac-
companied by nephrotic syndrome. Of note, FSGS with
nephrotic syndrome exhibits a grave prognosis; respon-
siveness to corticosteroids is not favorable compared to
minimal change disease (MCD) and a substantial number
of patients with FSGS develop ESRD, especially in African
Americans [7].
In 2003, D’Agati, et al. proposed 5 histologic variants
of FSGS based entirely on light microscopic findings; tip,
perihilar, cellular, collapsing, and not-otherwise specified
(NOS) [8]. This is known as the Columbia classification,
which has gained wide acceptance during the past decade.
To date, many investigators have tried to find differences
in the clinical characteristics and outcomes of FSGS pa-
tients according to these pathologic variants. In general,
the collapsing variant has been reported to have worse
renal survival rate compared to other variants, while the
tip variant shows the best prognosis and high rates of
complete remission [9,10]. However, the prevalence of the
5 variants differs depending on race and ethnicity [11]. In
fact, collapsing and cellular variants are more prevalent
in African Americans than other populations. In con-
trast, these lesions are relatively uncommon in Indian
and Dutch population [11,12]. In addition, there have been
few studies to define the clinical characteristics and out-
comes according to the Columbia classification involving
the East Asian population. Therefore, we conducted a
retrospective study to delineate the prevalence of the 5
FSGS variants and their clinical features and outcomes in
Korean adult patients with FSGS.
Methods
Ethics
This study was approved by the Institutional Review Board
(IRB) of Yonsei University Health System Clinical Trial
Center (IRB No; 4-2013-0436). This study was a retrospect-
ive medical record-based study and the IRB waived the re-
quirement for written consent from the patients.
Patient selection
A review of the medical records identified 147 patients
who were diagnosed with primary FSGS between January
2004 and February 2013 by renal biopsy in Yonsei Univer-
sity Severance hospital and National Health Insurance
Service Ilsan hospital in Korea. These patients did not
have another glomerular disease or other conditions that
were secondarily related to FSGS such as reflux, human
immunodeficiency virus (HIV) infection, sickle cell anemia,
surgical renal ablation, or solitary kidney. In addition,
we confirmed that the patients were not exposed to her-
oin, lithium, calcineurin-inhibitor, or pamidronate prior
to diagnosis. There was no familial FSGS in our medical
records. Among these patients, 36 patients were excludedfor following reasons; age < 18 years (n = 3), follow-up
duration < 6 months (n = 21), inadequate number of glom-
eruli < 7 (n = 6), and 24-h proteinuria < 0.5 g/day (n = 6).
Finally, 111 FSGS patients were included in the analysis
(Figure 1).
Pathologic and clinical data
All biopsied kidney tissues were reviewed by two experi-
enced pathologists, and confirmed as FSGS with segmental
scarring of at least one glomerulus and some parts of glom-
erular tufts according to the definition of FSGS. We classi-
fied subtypes of FSGS into tip, perihilar, cellular, collapsing,
and not-otherwise specified (NOS) by the Columbia classifi-
cation [8]. Foot process effacement on electron microscopy
(EM) was confirmed by reviewing initial pathologic report.
Demographic and clinical data included age at diagno-
sis, gender, comorbidities, height, weight, body mass
index (BMI), blood pressure, presence of nephrotic syn-
drome, serum creatinine, estimated glomerular filtration
rate (eGFR), serum albumin, total cholesterol, low dens-
ity lipoprotein (LDL) cholesterol, presence of hematuria,
random urine protein-to-creatinine ratio (UPCR), and 24-h
urinary protein excretion at the time of biopsy. We calcu-
lated eGFR using the CKD-EPI (Chronic Kidney Disease
Epidemiology Collaboration) equation [13]. Because 24-h
proteinuria was not available at all visits, follow-up data for
UPCR were collected. In addition, medications including
renin-angiotensin system (RAS) blockers, steroids, and
other immunosuppressants were recorded.
We defined hematuria as ≥ 3 red blood cells (RBC) per
high power field on urine microscopy. Nephrotic syn-
drome was defined as 24-h proteinuria > 3.5 g/day, hypo-
albuminemia (serum albumin ≤ 3.5 mg/dL), generalized
edema and hypercholesterolemia. Nephrotic range pro-
teinuria was defined as 24-h proteinuria > 3.5 g/day or
spot urine protein-to-creatinine ratio >3.5 g/g.
Study endpoints
All patients were followed up until Feb 28, 2013. Primary
endpoint was the composite of a doubling of baseline
serum creatinine concentration (D-sCr) or onset of ESRD.
D-sCr was defined as a sustained, greater than two-fold in-
crease in serum creatinine for at least three consecutive
measurements. Point of D-sCr was taken as the first among
these measurements. ESRD was defined as initiation of
dialysis or receiving transplantation. We also evaluated
complete (CR) and partial remission (PR) rates during
follow-up. CR was defined as < 0.3 g/g of UPCR and PR
was defined as > 50% reduction in proteinuria from
baseline amount of proteinuria.
Statistical analyses
Data analysis was performed using SPSS software for
Windows, version 20 (SPSS, Chicago, IL). All variables with
Figure 1 Flow diagram of the study.
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viation. Comparisons were made by Student’s t-tests or
one-way ANOVA for continuous variables and by the Chi-
square test for categorical variables as appropriate. The
Kolmogorov-Smirnov test was used to determine the nor-
mality of the distribution of parameters. Data that did not
show normal distribution were expressed as median and
interquartile range and were compared using the Mann–
Whitney test or Kruskal–Wallis test. We estimated the
event free renal survival rates of primary end point using
the Kaplan-Meier method and compared differences with
the log-rank test. Event free survival was calculated from
the date of renal biopsy to date of dialysis initiation, kidney
transplantation, or last follow-up date. The Cox propor-
tional hazards model was used to identify independent vari-
ables for event free survival. The results were expressed in
hazard ratios (HR) and 95% confidence intervals (CI). All
P-values were two-tailed and values < 0.05 were considered
statistically significant.
Results
Baseline characteristics
Demographic, clinical and laboratory data by the Columbia
classification in 111 patients are shown in Table 1.
The frequency of the five variants was 63% (n = 70) in
not-otherwise specified (NOS), 18% (n = 20) in tip, 15%
(n = 17) in perihilar, 3% (n = 3) in cellular, and 1% (n = 1)
in collapsing variants. Patients’ mean age at biopsy was
47.2 years and 39.6% were male. Sixty-three patients
(56.8%) had hypertension before FSGS was diagnosed.
Mean eGFR was 81.7 mL/min/1.73 m2 and median 24-h
proteinuria and was 3.02 g/day. Fifty (45.0%) patients
developed nephrotic syndrome at presentation (Table 1).
When we included the patients with follow-up dur-
ation < 6 months (n = 21), and 24-h proteinuria < 0.5 g/
day (n = 6), demographic and pathologic characteristics
are similar (Additional file 1: Table S1).Because there were only three cellular variants and one
collapsing variant, we did not include these variants in the
statistical analyses. There were no differences in age, sex,
BMI, blood pressure, and prior history of hypertension
among NOS, tip, and perihilar variants. Nephrotic syn-
drome occurred more frequently and the amount of pro-
teinuria was higher in tip variant compared to other
variants. In addition, total and LDL cholesterol levels were
significantly higher and serum albumin levels were signifi-
cantly lower in patients with tip variant than those with
other variants.
Treatment
Among 50 patients who had nephrotic-range proteinuria
over 3.5 g/day at presentation, 47 patients were started
on corticosteroid therapy at 1 mg/kg of body weight per
day (maximum 80 mg/day). Three patients used cyclospor-
ine as the first line treatment due to osteoporosis. Among
those treated with corticosteroids, complete and partial re-
mission were achieved in 17 (36.2%) and 8 (17.0%) patients,
respectively. Median duration of corticosteroids treatment
was 276 (163–486) days. In the remaining 22 patients who
did not respond to corticosteroids, adding cyclosporine re-
sulted in additional CR and PR in one and six patients,
respectively.
Most patients (94.6%) were treated with RAS blockers
and there was no difference in RAS blockers use among
the groups. However, corticosteroids were more commonly
prescribed (65.0%) in tip variant compared to other vari-
ants (P = 0.035).
Renal outcomes by the Columbia classification
Median follow up duration was 34.5 months and twenty-
seven patients were followed up more than 5 years. Six-
teen (14.4%) patients reached the composite of D-sCr or
ESRD and the overall 5-year event-free renal survival rate
was 76.8% (Figure 2A). Twelve (17.1%) patients with NOS
Table 1 Demogaphic, clinical and laboratory data by FSGS pathologic variants
Total NOS Tip Perihilar Cellular Collapsing P†
N (%) 111 70 (63.1) 20 (18.0) 17 (15.3) 3 (2.7) 1 (0.9)
Age (years) 47.2 ± 16.2 48.0 ± 15.0 44.8 ± 16.9 45.1 ± 19.0 45.3 ± 18.2 84.0 0.649
Sex Male (%) 44 (39.6) 29 (41.4) 7 (35.0) 6 (35.3) 2 (66.7) 0 (0.0) 0.818
Female (%) 67 (60.4) 41 (58.6) 13 (65.0) 11 (64.7) 1 (33.3) 1 (100.0)
BMI (kg/m2) 24.9 ± 3.9 24.8 ± 3.5 25.2 ± 4.5 25.3 ± 4.8 25.7 ± 4.2 23.8 0.837
SBP (mmHg) 133.1 ± 19.5 133.4 ± 19.8 133.8 ± 19.8 130.4 ± 17.3 140.0 ± 34.6 130.0 0.837
DBP (mmHg) 83.2 ± 15.7 83.9 ± 15.8 82.1 ± 11.9 81.4 ± 16.6 90.0 ± 35.3 72.0 0.784
MAP (mmHg) 99.9 ± 16.0 100.4 ± 16.2 99.3 ± 13.5 97.7 ± 15.6 106.8 ± 35.1 91.3 0.813
Hypertension (%) 63 (56.8) 40 (57.1) 9 (45.0) 11 (64.7) 2 (66.7) 1 (100.0) 0.462
Hematuria (%) 43 (38.7) 28 (40.0) 8 (40.0) 6 (35.3) 1 (33.3) 0 (0.0) 0.952
Nephrotic range proteinuria (%) 50 (45.0) 27 (38.6) 14 (70.0) 5 (29.4) 3 (100.0) 1 (100.0) 0.012
Nephrotic syndrome (%) 42 (37.8) 22 (31.4) 12 (60.0) 7 (41.2) 0 (0.0) 1 (100.0) 0.062
Cr (mg/dL) 1.28 ± 1.00 1.26 ± 0.81 0.97 ± 0.48 1.22 ± 0.52 2.11 ± 0.95 1.64 0.277
eGFR (mL/min/1.73 m2) 81.7 ± 33.0 81.4 ± 31.7 95.8 ± 34.3 75.8 ± 29.8 46.6 ± 23.4 37.8 0.202
Serum albumin (g/dL) 3.3 ± 1.0 3.4 ± 1.0 2.8 ± 1.0 3.7 ± 0.8 3.3 ± 0.6 1.9 0.018
T- chol (mg/dL) 248.3 ± 104.5 230.0 ± 89.6 340.6 ± 143.7 223.4 ± 52.7 204.0 ± 19.1 241.0 <0.001
LDL-chol (mg/dL) 146.8 ± 80.2 137.5 ± 68.2 215.7 ± 114.1 109.6 ± 39.3 116.5 ± 17.9 162.0 0.002
Proteinuria
UPCR (g/g)* 3.02 (1.42-5.54) 2.17 (1.33–5.10) 4.67 (2.43-8.26) 1.85 (0.95-4.24) 5.54 (3.94-16.04) 16.67 0.05
24 hr protein (g/day)* 2.90 (1.57-6.32) 2.86 (1.32-5.73) 4.28 (2.07-7.53) 2.32 (0.95-5.20) 4.12 (1.85-12.07) 4.28 0.35
TA-P (g/g)* 1.41 (0.78-3.42) 1.34 (0.73-3.21) 1.67 (0.85-3.46) 1.46 (0.64-4.14) 1.34 (1.11-5.4) 4.85 0.70
Time to renal biopsy (mo) 0 (0 – 2) 0 (0 – 2) 0 (0 – 2) 0 (0 – 2) 0 (0 – 2) 0.0 0.965
Treatment
RAS blockades (%) 105 (94.6) 66 (94.3) 19 (95.0) 16 (94.1) 3 (100.0) 1 (100.0) 0.991
Steroid (%) 47 (42.3) 23 (32.9) 13 (65.0) 7 (41.2) 3 (100.0) 1 (100.0) 0.035
Responder (n) 25 12 9 2 1 1
Resistance (n) 22 11 4 5 2 0
Cyclosporine (%) 25 (22.5) 13 (18.6) 6 (30.0) 4 (23.5) 2 (66.7) 0 (0.0) 0.431
MMF (n) 2 1 0 1 0 0
Cyclophosphamide (n) 1 1 0 0 0 0
All data are expressed as mean ± SD or *median and interquartile range.
Abbreviations: FSGS focal segmental glomerulosclerosis, NOS not otherwise specified, SBP systolic blood pressure, DBP diastolic blood pressure, MAP mean arterial
pressure, S-Cr serum creatinine, eGFR estimated glomerular filtration rate, T-chol total cholesterol, LDL-chol low-density lipoprotein cholesterol, UPCR urine
protein-to-creatinine ratio, TA-P time-averaged proteinuria, RAS renin-angiotensin system, MMF mycophenolate mofetil.
†; P-values were obtained from comparisons between NOS, tip, and perihilar variants.
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pared to 2 (11.8%) with perihilar variant and 1 (5.0%) with
tip variant (Table 2, P = 0.370). A Kaplan-Meier curve also
showed that overall renal survival rates were not statisti-
cally significant between patients with NOS, tip, and peri-
hilar variants (Figure 2B, P = 0.616). Multivariable analysis
after adjustment of age, sex, hypertension, eGFR, protein-
uria, and immunosuppression showed no difference in the
development of primary outcome among the three groups
(Table 3). Among three patients with cellular variant, two
patients showed kidney impairment at presentation (eGFRof 24.6 and 36.2 mL/min/1.73 m2, respectively) and one
reached the composite outcome. At two patients with cel-
lular variant showed UPCR 16.04 and 3.94 g/g at the time
of biopsy, UPCR were reduced to 2.84 and 1.93 g/g after
treatment of corticosteroid or cyclosporine, respectively.
One patient with collapsing variant presented nephrotic
syndrome and exhibited an eGFR of 38 mL/min/1.73 m2
and UPCR of 16.7 g/g at the time of biopsy. Twelve-
month corticosteroid treatment resulted in reduction of
UPCR to 1.43 g/g and improvement of eGFR to 38 mL/
min/1.73 m2 in this patient.
Figure 2 Kaplan-Meier plots for (A) overall event free renal survival and (B) event free renal survival by FSGS pathologic variants. Overall
5-renal survival rate was 76.8%. There were no significant difference in renal survival rates between patients with NOS, perihilar, and tip variants.
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In terms of remission rates, CR and PR were achieved in
29 (26.1%) and 35 (31.5%) patients, respectively. CR or
PR was attained in 16 (80.0%) patients with tip variant
compared to 38 (54.3%) with NOS variant (P = 0.038)
and 7 (41.2%) with perihilar variant (P = 0.015) (Table 2).
In addition, CR was more frequently achieved in patients
with tip variant than those with NOS (P = 0.018) or peri-
hilar (P = 0.040) variants. A higher rate of PR was also
observed in patients with tip variant compared to those
with other variants, but did not reach statistical signifi-
cance. Kaplan-Meier plots also produced the same re-
sults (Figure 3A and B). In unadjusted Cox models, tip
variant was associated with a significantly increased
probability of achieving CR (HR, 2.616; 95% CI, 1.184-
5.778; P = 0.017) and CR or PR (HR, 1.809; 95% CI,
1.007-3.250; P = 0.047). Multivariable analysis adjusted
for age, sex, eGFR, proteinuria, and immunosuppression
showed that tip variant conferred a 2.4-fold higher prob-
ability of achieving CR (P = 0.044, Table 4). A similarTable 2 Renal outcomes by FSGS pathologic variants
NOS
N (%) /1000 pys N (%
Composite* 12 (17.1%) 47.6 1 (5.
D-SCr 12 (17.1%) 47.6 1 (5.
ESRD 8 (11.4%) 31.3 1 (5.
CR or PR 38 (54.3%) 337.5 16 (80.0
CR 16 (22.9%) 84.7 10 (50.0
PR 22 (31.4%) 153.8 6 (30
Relapse 8 (11.4%) 3 (15
*Composite outcome was a doubling of the baseline serum creatinine concentratio
†, P = 0.038 vs. NOS; ‡, P = 0.015 vs. perihilar; §, P = 0.018 vs. NOS; #, P = 0.040 vs. pe
Abbreviations: NOS not-otherwise specified, D-SCr doubling of the baseline creatinine l
pys patient-years.
Footnote; Thirty-five patients achieved partial remission. Thirty-two cases are includ
and a patient with collapsing variant.association was also observed when CR or PR was en-
tered together as a dependent outcome variable, but the
result was not statistically significant.
Discussion
In this study, we sought to delineate clinical features and
outcomes according to the Columbia classification in
111 Korean adult patients with primary FSGS. We showed
that cellular and collapsing variants were uncommon in
our cohort and overall outcome was not affected by patho-
logic variants. However, nephrotic syndrome was the most
common in tip variant, which exhibited favorable outcome
in terms of achieving remission. The present study pro-
vided distinct clinical features of FSGS in the Korean
population for the first time and reinforced the findings of
previous studies indicating that pathologic variants of
FSGS may have different prognostic implications.
As aforementioned, the Columbia classification has been
used worldwide in patients with FSGS. However, many
studies have clearly shown that the relative frequency ofTip Perihilar
) /1000 pys N (%) /1000 pys
0%) 17.8 2 (11.8%) 45.2
0%) 17.8 2 (11.8%) 45.2
0%) 17.6 0 (0.0%) 0.0
%)†, ‡ 678.0 7 (41.2%) 220.8
%)§, # 305.8 3 (17.6%) 74.1
.0%) 155.8 4 (23.5%) 112.4
.0%) 1 (5.9%)
n or ESRD.
rihilar.
evels, ESRD end-stage renal disease, CR complete remission, PR partial remission,
ed in Table 2 and the remaining 3 cases are two patients with cellular variant
Table 3 Multivariable Cox regression analyses for the composite outcome
Model 1 Model 2 Model 3
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Sex (vs. female) 0.658 (0.189 – 2.292) 0.511 0.821 (0.215 – 3.132) 0.773 0.741 (0.175 – 3.149) 0.685
Age (per 1 year increase) 0.952 (0.914 – 0.992) 0.020 0.950 (0.911 – 0.991) 0.017 0.945 (0.902 – 0.991) 0.019
HTN (vs. no) 0.675 (0.184 – 2.476) 0.553 0.793 (0.194 – 3.242) 0.746 0.663 (0.138 – 3.198) 0.609
TAP (per 1 g/g increase) 1.887 (1.399 – 2.546) <0.001 1.881 (1.392 – 2.543) <0.001 1.979 (1.382 – 2.832) <0.001
eGFR (per 1 ml/min/1.73 m2 increase) 0.955 (0.932 – 0.979) <0.001 0.951 (0.923 – 0.978) 0.001 0.952 (0.926 – 0.978) <0.001
Pathologic variants
NOS – – Reference Reference
Perihilar – – 1.054 (0.189 – 5.862) 0.952 1.019 (0.183 – 5.664) 0.983
Tip – – 1.699 (0.160 – 18.052) 0.660 1.657 (0.162 – 16.949) 0.670
Immunosuppression (vs. no) – – 0.622 (0.120 – 3.225) 0.572
Abbreviations: HTN hypertension, eGFR estimated glomerular filtration rate, TAP time-averaged proteinuria.
Model 1: sex, age, hypertension, TAP, and eGFR.
Model 2: Model 1 + pathologic variants.
Model 3: Model 2 + immunosuppression.
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[4,9,11,12,14-17]. It is well known that collapsing and cellu-
lar variants are more common in African Americans than
other populations, while whites are more likely to have tip
variant [9,14]. However, collapsing and cellular variants
were not common in the present study. This finding is cor-
roborated by other previous studies showing a low fre-
quency of collapsing and cellular variants in non-African
American populations [11,12]. To date, there have been
few studies to evaluate the prevalence of the five pathologic
variants by the Columbia classification in Asian popula-
tions. In keeping with our findings, NOS variant was the
most common and collapsing variant was uncommon in
an Indian study and two Chinese studies [11,18,19]. How-
ever, four Asian studies were not in accordance with the
frequency of cellular variant. Our cohort showed the lowest
(2.7%) frequency, while it was the highest for the Chinese
studies (14.4% and 25.5%) and intermediate between theFigure 3 Kaplan-Meier plots for (A) complete remission (CR) and (B) c
higher probability of achieving CR and CR or PR.two populations for the Indian study (8.0%). Interestingly,
there was a substantial discrepancy in the frequency of cel-
lular variant between Korean and Chinese populations.
Moreover, the two Chinese studies reported a 10% differ-
ence in the frequency although they were the same popula-
tion. Of note, there may be misclassification of cellular
variant as tip variant because cellular lesions can exist
within the tuft in tip variants and intracapillary expansile
foam cells can be observed in both variants depending on
location; either at the polar domain in tip variants or at any
other location in the cellular variants. In fact, Stokes et al.
[17] emphasized the importance of adequate sampling and
sectioning because about 30% of cellular variants were re-
classified as tip variants by deeper sectioning of the biopsy.
On the other hand, there has been controversy about
whether tip and cellular variants may be two stages of a
single entity identified at different points of time [11,17].
Due to the retrospective nature of the study, it is unknownomplete or partial remission (PR). Patients with tip lesion had
Table 4 Unadjusted and adjusted Cox models for remission
Unadjusted Adjusted*
HR (95% CI) P-value HR (95% CI) P-value
CR
Pathologic variants
NOS Reference Reference
Perihilar 0.736 (0.214 – 2.534) 0.627 0.963 (0.262 – 3.535) 0.954
Tip 2.616 (1.184 – 5.778) 0.017 2.417 (1.025 – 5.703) 0.044
CR or PR
Pathologic variants
NOS Reference Reference
Perihilar 0.616 (0.274 – 1.384) 0.241 0.691 (0.303 – 1.580) 0.381
Tip 1.809 (1.007 – 3.250) 0.047 1.632 (0.870 – 3.061) 0.127
*Adjusted for age, sex, eGFR, proteinuria, and immunosuppression.
Abbreviations: CR complete remission, PR partial remission, NOS not otherwise specified.
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in more identification of tip variants in the Chinese stud-
ies. Nevertheless, our findings were consistent with most
previous studies showing that cellular variant is uncom-
mon. Further studies involving other Asian populations
are warranted to elucidate whether cellular variant is as
common in Asian populations as in African Americans.
In general, collapsing variant has the worst prognosis
among the five variants, whereas tip variant has the best
prognosis. Cellular variant shows an intermediate progno-
sis between the two variants. Unfortunately, the present
study did not confirm these observations because of the
limited number of collapsing and cellular variants. Two
patients with cellular variant and one patient with collaps-
ing variant had substantial amounts of proteinuria and
kidney impairment at presentation. This finding suggests
that clinical outcomes of these two variants may not be
favorable, and rare frequency of these two variants may
draw a favorable prognosis. However, long-term follow-up
studies with a larger sample size are required to determine
the prognosis.
A number of studies have reported that tip variant has
clinical features similar to that of minimal change disease
and its responsiveness to corticosteroids is favorable; thus,
tip variant is considered to have good prognosis [10,20].
In line with this, in the present study, tip variant was sig-
nificantly associated with achieving CR or PR. In addition,
only 1 (5.0%) patient with tip variant reached the compos-
ite outcome compared to 12 (17.1%) patients with NOS
variant and 2 (11.8%) patients with perihilar variant. How-
ever, this difference was not statistically significant pos-
sibly because of the small number of patients. Of note,
previous studies compared tip variant with collapsing or
cellular variants [10,14], which are known to be associated
with poor outcome. As aforementioned, in our cohort,
these two variants were very rare; thus, detailed analysis toprove prognostic superiority of tip variant to other vari-
ants was not feasible. Because NOS and perihilar variants
generally present subnephrotic range proteinuria and less
severe clinical features compared to collapsing variant, it
is possible that tip variant may not confer an advantage in
renal outcome over NOS or perihilar variants depending
on the characteristics of the study subjects. In fact, two
previous studies did not demonstrate that renal outcome
of tip variant is better than that of NOS variant [10,14].
Nevertheless, given the significant correlation between re-
mission rate and renal survival, it can be expected that tip
variant may have favorable long-term outcome.
Perihilar variant is generally considered secondary FSGS.
In the present study, patients with this variant comprised
15.3% of all patients and had no evidence of reflux ne-
phropathy, sickle cell anemia, surgical ablation, or renal
agenesis. Eleven (64.7%) patients were diagnosed with
hypertension before renal biopsy, and some of them
showed histologic features of hypertensive nephrosclero-
sis, which might contribute to adaptive change in glom-
erular capillaries. In our cohort, obesity was unlikely to be
associated with perihilar variant because mean BMI was
25.3 kg/m2, which was not different from patients with
other variants. Nephrotic syndrome developed in 41.2% of
patients with perihilar variant. In addition, the clinical out-
come of these patients was favorable because 5-year renal
survival rate was 66.7% (Figure 2B) and only two (11.8%)
patients reached the composite outcome during follow-
up. Our findings were consistent with the results of previ-
ous studies showing that the frequency of nephrotic
syndrome in perihilar variant varies from 25% to 55%
[9,12] and 5-year renal survival rate was reported up to
55% [12].
Our study has some limitations. First, this is a retrospect-
ive study with a small sample size. In particular, a small
number of patients with cellular and collapsing variants
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not analyze these patients to prove that collapsing or cellu-
lar variant exhibit the worst prognosis as previously re-
ported. For the same reason, tip variant was not associated
with a significantly decreased risk of reaching the compos-
ite outcome. Second, we confirmed foot process efface-
ment on EM reviewed initial pathologic reports due to lack
of available EM photography in some patients. Third, the
retrospective nature of the study did not clearly suggest
a therapeutic approach by histologic variants. In fact, in
many cases, physicians usually decide whether or not to
treat with immunosuppression depending on clinical in-
dicators such as heavy proteinuria or rapid deterioration
of kidney function. In addition, there has been a concern
about the usefulness of pathologic findings in predicting
future outcome. Several studies showed that response rate
to treatment in collapsing FSGS was not as poor as ex-
pected, ranging as high as 40 to 64% [1,12]. In addition,
Chun et al., reported a 92% remission rate in patients with
celluar lesions involving < 20% of glomeruli, compared to
only 33% in patients with cellular lesions in ≥ 20% of
glomeruli [14], suggesting that cellular lesions per se do
not universally portend a bad prognosis. In line with this
notion, in the present study, entering CR or PR was sig-
nificantly associated with a decreased risk of reaching
the composite outcome (HR, 0.03; 95% CI, 0.002-0.594;
P = 0.021, data not shown), while pathologic variants
were not. Finally, there was relatively small number of
patients presenting with nephrotic syndrome in this
study. This is partly attributed to a lack of patients with
collapsing and cellular variants in our study. In general,
these two variants show nephrotic syndrome. In contrast,
subnephrotic proteinuria is more common in patients with
NOS and perihilar variants, which comprised 78.4% of our
cohort. Such characteristics of our cohort may explain the
low prevalence of nephrotic syndrome in this study.
Conclusion
In conclusion, the present study might help illuminate
common clinical features of FSGS with a rare frequency
of cellular and collapsing variants in the Korean popula-
tion. Although pathologic variants were not associated
with overall outcome, tip variant showed favorable out-
come in terms of achieving remission. However, since
present study includes very small number of patients,
further studies with a larger sample size are required to
delineate long-term outcome and response to treatment
of the pathologic variants.
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